Sai Life Sciences · NSE: SAILIFE · BSE: 544306
Q3 FY26 results · Oct–Dec 2025
Sai Life Sciences reported revenue from operations of ₹556.46 crore (up 26.5% from Q3 FY25) and net profit of ₹100.38 crore (up 86.4% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 556.46 | 439.78 | +26.5% | 537.47 | +3.5% |
| Other income | 8.38 | 9.12 | −8.1% | 15.32 | −45.3% |
| Total income | 564.84 | 448.89 | +25.8% | 552.79 | +2.2% |
| Profit before tax | 134.17 | 71.65 | +87.3% | 112.05 | +19.7% |
| Net profit for the period | 100.38 | 53.85 | +86.4% | 83.84 | +19.7% |
| EPS, basic (₹) | 4.77 | 2.89 | +65.1% | 4.01 | +19.0% |
| Net margin (%) | 18.0 | 12.2 | 15.6 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 549.18 | 428.60 | +28.1% | 526.67 | +4.3% |
| Other income | 8.45 | 9.45 | −10.6% | 14.93 | −43.4% |
| Total income | 557.63 | 438.05 | +27.3% | 541.60 | +3.0% |
| Profit before tax | 130.47 | 67.91 | +92.1% | 110.87 | +17.7% |
| Net profit for the period | 97.63 | 51.06 | +91.2% | 82.95 | +17.7% |
| EPS, basic (₹) | 4.64 | 2.74 | +69.3% | 3.97 | +16.9% |
| Net margin (%) | 17.8 | 11.9 | 15.7 |
Consolidated
- Filed with BSE
- 05 Feb 2026, 21:36 IST
- Board meeting
- 05 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 Feb 2026, 21:36 IST
- Board meeting
- 05 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE